GoodRx adds IQVIA CFO Bruehlman to board; Bezdek extends contract with no severance

GoodRx Holdings, Inc.

Ronald E. Bruehlman (IQVIA CFO) elected to Board and as Audit & Risk Committee chair, effective Nov 8, 2024.
Director Julie Bradley resigns Nov 8 due to personal commitments; no disagreement with company.
Chief Mission Officer Douglas Hirsch ends employment Oct 25; stays on Board as non-employee director.
Chairman Trevor Bezdek's employment extended through Oct 25, 2025; 2025 cash bonus target 100% of salary; no severance.
Bruehlman receives $420K RSU (3-year vest) and $132K pro-rated annual RSU; eligible for standard director cash retainers.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ronald E. Bruehlman

Director

GDRX · GoodRx Holdings, Inc.

Effective: 2024-11-08
Filed: October 28, 2024, 7:59 PM ET

On October 25, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ronald E. Bruehlman as a Class III director, effective as of the Effective Date, to fill the vacancy on the Board created by the resignation of Julie Bradley.

Departed

Julie Bradley

Director

GDRX · GoodRx Holdings, Inc.

Effective: 2024-11-08
Successor: Ronald E. Bruehlman
Filed: October 28, 2024, 7:59 PM ET

On October 22, 2024, Julie Bradley notified GoodRx Holdings, Inc. (the “Company”) of her decision to resign as a member of the Board of Directors of the Company (the “Board”), including from her service on the Board’s Audit and Risk Committee, effective as of November 8, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald E. Bruehlman was elected as Director at GoodRx Holdings, Inc..

Action: elected
Role: Director

Exact text from the filing

On October 25, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ronald E. Bruehlman as a Class III director, effective as of the Effective Date, to fill the vacancy on the Board created by the resignation of Julie Bradley.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Julie Bradley resigned as Director at GoodRx Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 22, 2024, Julie Bradley notified GoodRx Holdings, Inc. (the “Company”) of her decision to resign as a member of the Board of Directors of the Company (the “Board”), including from her service on the Board’s Audit and Risk Committee, effective as of November 8, 2024 (the “Effective Date”).

View on SEC.gov

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-24-000188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.